Cagrilintide

Common side effects:

• Nausea, particularly during the initial dose escalation phase.
• Vomiting and general gastrointestinal discomfort.
• Diarrhea or constipation.
• Decreased appetite leading to unintended caloric deficits.
• Injection site reactions such as mild redness or swelling.

Rare or serious side effects:

• Severe hypoglycemia, especially when combined with other anti-diabetic medications.
• Gallbladder disease or gallstones due to rapid weight loss.
• Potential risk of pancreatitis, common among incretin and amylin mimetics.
• Allergic reactions or hypersensitivity to the peptide formulation.

Amylin receptor agonism drives the primary mechanism of the Cagrilintide peptide, acting as a long-acting synthetic analog of the pancreatic hormone amylin. Upon subcutaneous administration, it crosses the blood-brain barrier to activate amylin receptors 1 and 3 in the hindbrain, which directly regulates satiety and reduces food intake Carvas AO et al., 2025. This targeted neural activation delays gastric emptying and suppresses postprandial glucagon secretion, creating a sustained feeling of fullness.

Synergistic metabolic pathways are engaged when Cagrilintide is combined with GLP-1 receptor agonists like semaglutide. While GLP-1 analogs primarily target the hypothalamus to reduce hunger, Cagrilintide's action on the hindbrain provides a complementary mechanism for appetite suppression Enebo LB et al., 2021. This dual-receptor approach maximizes weight loss efficacy and improves overall glycemic control without overlapping receptor competition.

Development and discovery of Cagrilintide stemmed from the need for more effective, long-acting anti-obesity medications. Researchers engineered this synthetic amylin analog to overcome the short half-life of native human amylin, utilizing acylation technology to allow for once-weekly subcutaneous dosing Kruse T et al., 2021. This breakthrough enabled sustained therapeutic levels, making it a viable candidate for chronic weight management.

Clinical and regulatory milestones are rapidly advancing, with the peptide currently in late-stage Phase 3 clinical trials. Novo Nordisk is heavily investigating the co-administration of Cagrilintide and semaglutide for both obesity and type 2 diabetes Davies MJ et al., 2025. While not yet FDA-approved for general use, its promising safety and efficacy profiles in Phase 2 trials suggest it may soon become a cornerstone treatment in metabolic medicine.